Petra W. Duda - Concepedia

Author

Petra W. Duda

Harvard University

Also Known As

Karen Zakalik, P Duda, P. Duda, P. W. Duda, P.W Duda, P.W. Duda, Petra Duda, Petra W Duda, Petra W. DUDA, Petra W. Duda

Publications

Citations

H-Index

Concepts

All Affiliations

Harvard University UCB Pharma (United States)George Washington University Biogen (United States)AVEO Oncology (United States)

About

Petra W. Duda is an author at Harvard University specializing in medicine, multiple sclerosis, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	884
2	Health Sciences	3	3	239
3	Allergy	1	1	25
4	Biochemistry	1	1	32
5	Clinical Immunology	1	1	82

Petra W. Duda

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis Petra W. Duda, M. Schmied, Sandra L. Cook, Journal of Clinical Investigation	2000	418
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function Bhupendra Khatri, S. Man, Gavin Giovannoni, Neurology	2009	276
Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs L Barrera, E Cooreman, de Dieu Iragena J, Drug SafetyTherapeutic Drug MonitoringMedicineTuberculosisDrug Test	2008	227
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study James F. Howard, Saskia Bresch, Angela Genge, The Lancet Neurology MedicineSurgeryClinical TrialsGeneralised Myasthenia Gravis	2023	213
MS disease activity in RESTORE Robert J. Fox, Bruce Cree, J. de Sèze, Neurology	2014	188
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis James F. Howard, Richard J. Nowak, Gil I. Wolfe, JAMA Neurology	2020	176
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes David B. Clifford, Avindra Nath, Paola Cinque, Journal of NeuroVirology Neurological DisorderPml OutcomesCsf Jcv DnaImmunologyClinical Neurology	2013	162
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study Paul O’Connor, Andrew Goodman, Ludwig Kappos, Neurology	2014	134
Cross‐sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment Gary Cutter, Haichang Xin, Inmaculada Aban, Muscle & Nerve	2019	86
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis Michael D. Kaufman, Gabriel Pardo, Howard Rossman, Journal of the Neurological Sciences Clinical ImmunologyAutoimmune DiseaseImmunologyImmunization ResponsesAutoimmunity	2014	82

Page 1